Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07207707 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

A Phase 1 study of Solid Tumor Malignancies, sponsored by Kumquat Biosciences.

Recruiting
Registry status
Phase 1
Development phase
78
Enrollment target
12
Study locations

NCT07207707 is a Phase 1 study of Solid Tumor Malignancies that is actively recruiting participants, run by Kumquat Biosciences. The registered enrollment target is 78 participants, below the 189-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (59% lower). The trial reports 12 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07207707, a Phase 1 study of Solid Tumor Malignancies, is actively recruiting participants, sponsored by Kumquat Biosciences.

RECRUITING
Registry status
Phase 1
Development phase
78 participants
Enrollment target
12
Study locations

Study Summary

The goal of this trial is to learn if KQB548 works to treat patients with advanced solid malignancies with a KRAS G12D mutation. It will also learn about the safety of KQB548. The main questions it aims to answer are: * What is the safe dose of KQB548? * Does KQB548 decrease the size of the tumor? * What happens to KQB548 in the body?

Conditions Studied

Solid Tumor Malignancies

Interventions

  • DRUG KQB548

Study Locations (12)

Texas

  • NEXT Oncology - Austin - Austin
  • MD Anderson Cancer Center - Houston
  • NEXT Oncology - Dallas - Irving
  • NEXT Oncology - San Antonio - San Antonio

California

  • University of California, San Diego - La Jolla
  • University of California, Los Angeles - Los Angeles

Colorado

  • SCRI - Denver - Denver

Florida

  • University of Miami - Sylvester Comprehensive Cancer Center - Miami

Michigan

  • START Midwest - Grand Rapids

Ohio

  • The Christ Hospital - Cincinnati

Utah

  • University of Utah - Huntsman Cancer Institute - Salt Lake City

Virginia

  • NEXT Virginia - Fairfax

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2025-09-16
Est. Completion 2027-03
Phase Phase 1

Sponsor

Kumquat Biosciences

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07207707

The ClinicalTrials.gov registry entry for NCT07207707 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (59% lower). The listed sponsor is Kumquat Biosciences, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumor Malignancies appearing as the primary indexed condition, and to 1 intervention - of which KQB548 is the first listed.

NCT07207707 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Texas, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT07207707 about?

NCT07207707 is a clinical study titled "A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies". The goal of this trial is to learn if KQB548 works to treat patients with advanced solid malignancies with a KRAS G12D mutation. It will also learn about the safety of KQB548. The main questions it aims to answer are: * What is the safe dose of KQB548? * Does KQB548 decrease the size of the tumor? ...

What is the current status of trial NCT07207707?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2025-09-16. Estimated completion is 2027-03.

What conditions does trial NCT07207707 study?

This clinical trial studies the following conditions: Solid Tumor Malignancies.

What interventions are being tested in trial NCT07207707?

The interventions under investigation include: KQB548 (DRUG).

Who is sponsoring clinical trial NCT07207707?

This trial is sponsored by Kumquat Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07207707 being conducted?

This trial has 12 study locations across California, Colorado, Florida, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor Malignancies

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor Malignancies

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.